Company / Interest Expense
BridgeBio Pharma, Inc. Interest Expense History
FY2017-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$34.3M
FY2024
5-year range
$8.8M / $80.4M
FY2020-FY2024
Trend
-26.6%
vs FY2023
Sector context
#16 of 44
Health Care
What the data says
At $34M, BridgeBio Pharma, Inc.'s interest expense ranks #29 of 44 in the Health Care sector. Interest Expense has fluctuated over the past 8 years, ranging from $13,000 in FY2017 to $80M in FY2022.
Based on SEC 10-K filings.
$34M in FY2024 with a 5-year CAGR of +31.4%.
Improved from $80M to $34M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- +57.6%
- 5-Year CAGR
- +31.4%
- 10-Year CAGR
- -
Sector benchmark
#29 of 44 in Health CareTop 64% of 44This company $34.3M Sector average $291.0M
▼
-88.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +31.4%, indicating consistent growth.
- In FY2024, interest expense decreased 26.6% year-over-year.
- Ranks #16 out of 44 companies in the Health Care sector.
- Peak interest expense was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $34.3M | -26.6% |
| FY2023 | $46.8M | -41.8% |
| FY2022 | $80.4M | +817.7% |
| FY2021 | $8.8M | -76.1% |
| FY2020 | $36.7M | +318.2% |
| FY2019 | $8.8M | +244.1% |
| FY2018 | $2.5M | +19492.3% |
| FY2017 | $13.0K | - |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026